What is Cordella?
Cordella, operating under the umbrella of Endotronix, Inc., provides an integrated platform designed to address the complex needs of patients suffering from advanced heart failure. The company's flagship Cordella Heart Failure System represents a significant leap in remote patient monitoring, combining cloud-based disease management data with a breakthrough implantable wireless pulmonary artery pressure sensor. This technology enables clinicians to perform at-home hemodynamic management, facilitating early detection of worsening conditions and potentially reducing hospital readmission rates. By bridging the gap between clinical intervention and patient-centric care, Cordella is effectively redefining the standard of care for chronic heart failure management.
How much funding has Cordella raised?
Cordella has raised a total of $128.7M across 10 funding rounds:
Debt
$1.2M
Private Equity
$1.6M
Debt
$2.2M
Debt
$3M
Series B
$3M
Series C
$32M
Debt
$12M
Series D
$70M
Debt
$2M
Debt (2013): $1.2M, investors not publicly disclosed
Private Equity (2014): $1.6M, investors not publicly disclosed
Debt (2014): $2.2M, investors not publicly disclosed
Debt (2015): $3M, investors not publicly disclosed
Series B (2015): $3M, investors not publicly disclosed
Series C (2016): $32M led by APERTURE Venture Partners, Lumira Capital, SV Life Sciences, and BioVentures Investors
Debt (2017): $12M supported by Silicon Valley Bank
Series D (2019): $70M featuring Seroba Life Sciences, APERTURE Venture Partners, Lumira Capital, Bioventures Investors, Wanxiang Healthcare Investments, OSF Ventures, Skydeck LLC, Life Sciences Partners, and SV Health Investors
Debt (2020): $2M backed by PPP
Key Investors in Cordella
Seroba Life Sciences
A European life sciences venture capital firm focused on investing in winning innovations in biotech and medtech to help entrepreneurs realize their ambitions.
APERTURE Venture Partners
A healthcare-focused investment firm dedicated to collaborating with exceptional entrepreneurs to develop innovative companies in the medical device and diagnostic sectors.
SV Health Investors
A specialist investment firm backing innovative health care and life science companies, providing capital, sector expertise, and active support from early growth through scale.
What's next for Cordella?
Looking ahead, the infusion of capital from the latest funding round is expected to accelerate the commercial expansion of the Cordella Heart Failure System. As the company moves deeper into the enterprise-level lifecycle stage, strategic priorities will likely include expanding clinical adoption, enhancing data analytics capabilities, and navigating the regulatory pathways for broader market penetration. The continued support from specialized healthcare investors provides the necessary runway to solidify Cordella's market position, ensuring that its innovative hemodynamic monitoring tools reach a wider patient demographic while maintaining the high standards of clinical efficacy required in the competitive MedTech industry.
See full Cordella company page
